Suchergebnisse - "Litton, Jennifer K"

PubPharm (13)

1

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer : Results of a Phase II Study

enthalten in: The oncologist | 2023

von Litton, J. | Beck, J. | Jones, J. | +13

2

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2022

von Blum, J. | Laird, A. | Litton, J. | +14

3

Breast Radiation Therapy-Related Treatment Outcomes in Patients With or Without Germline Mutations on Multigene Panel Testing

enthalten in: International journal of radiation oncology, biology, physics | 2022

von Chapman, B. | Liu, D. | Shen, Y. | +16

4

Outcomes After Breast Radiation Therapy in a Diverse Patient Cohort With a Germline BRCA1/2 Mutation

enthalten in: International journal of radiation oncology, biology, physics | 2022

von Chapman, B. | Liu, D. | Shen, Y. | +16

5

Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer

enthalten in: Expert opinion on pharmacotherapy | 2021

von Hobbs, E. | Litton, J. | Yap, T.

6

Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2020

von Litton, J. | Scoggins, M. | Hess, K. | +16

7

Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer

enthalten in: Cancer medicine | 2018

von Elsayegh, N. | Webster, R. | Gutierrez Barrera, A. | +5

8

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer

enthalten in: Cancer research | 2018

von Carey, J. | Karakas, C. | Bui, T. | +8

9

A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2017

von Evans, K. | Yuca, E. | Akcakanat, A. | +13

10

BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing

enthalten in: The oncologist | 2015

von Mitri, Z. | Jackson, M. | Garby, C. | +7

CommentIn: Oncologist. 2015 Jun;20(6):584-5. - PMID 25986243